Investigator

Bauke Ylstra

Senior researcher · i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Intercellular Communication and Cancer

About

Research Interests

BYBauke Ylstra
Papers(1)
Two types of primary …
Collaborators(2)
Femke SimmerMarjolijn J. L. Ligte…
Institutions(1)
Radboud University Me…

Papers

Two types of primary mucinous ovarian tumors can be distinguished based on their origin

The origin of primary mucinous ovarian tumors is unknown. We explore the hypothesis that they originate from either Brenner tumors or teratomas and examine differences between the tumors that arise in these settings. A total of 104 Brenner tumor-associated mucinous tumors and 58 teratoma-associated mucinous tumors were analyzed. Immunohistochemistry for 21 antigens and fluorescence in situ hybridization for ERBB2 and MYC were performed. Genome-wide copy number analysis and mutation analysis for 56 cancer-related genes was carried out on a subset of mucinous ovarian tumors and their complementary Brenner tumor or teratoma. Patients with teratoma-associated mucinous tumors were significantly younger than patients with Brenner tumor-associated mucinous tumors (43 vs. 61 years). During progression from cystadenoma to atypical proliferative mucinous (borderline) tumor to carcinoma expression of typical gastrointestinal markers was increased in both Brenner tumor-associated and teratoma-associated mucinous tumors. Brenner tumor-associated mucinous tumors showed more frequently calcifications and Walthard cell nests, rarely expressed SATB2 and showed more often co-deletion of CDKN2A and MTAP. Teratoma-associated mucinous tumors were characterized by mucinous stromal dissection, SATB2 expression and RNF43 mutations. Other frequent mutations in both Brenner tumor-associated and teratoma-associated mucinous tumors were TP53 and KRAS mutations. Based on identical mutations or copy number profiles clonal relationships were indicated in two mucinous tumors and their associated Brenner tumor. Teratomas and Brenner tumors give rise to different subtypes of mucinous ovarian tumors. Subsequent progression pathways are comparable since both Brenner tumor-associated and teratoma-associated mucinous tumors develop a gastrointestinal immunophenotype during progression and show early mutations in KRAS and TP53. Teratoma-associated mucinous tumors may more closely resemble true gastrointestinal tumors, indicated by their expression of SATB2 and the presence of RNF43 mutations.

348Works
1Papers
2Collaborators
Colorectal NeoplasmsBiomarkers, TumorPrognosisAdenocarcinomaNeoplasmsBrain NeoplasmsDisease ProgressionNeoplasm Recurrence, Local

Positions

2023–

Senior researcher

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · Intercellular Communication and Cancer

2018–

Director Tumor Genome Analysis Core

Amsterdam UMC · Department of Pathology

2001–

Director Tumor Genome Analysis Core

VU medisch centrum · Department of Pathology

2023–

consultant

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · IPATIMUP-diagnostics

2019–

Director Doctoral School CCA-VU

Cancer Center Amsterdam · Vrije Universiteit (VU)

1998–

Assistant Research Biochemist,

UC-San Francisco · Comprehensive Cancer Center

1990–

Research Assistant

Campus Vienna Biocenter · Microbiology & Genetics

Education

1998

Post-doc

UC Berkeley · Biology

1995

PhD

VU University Amsterdam · Genetics

1991

MSc

VU University Amsterdam · Undergraduate

1988

BSc

University of Amsterdam Swammerdam Institute for Life Sciences · Biology & Physics

Country

NL

Keywords
tumor genome analysis